Provided by Tiger Trade Technology Pte. Ltd.

BioAtla, Inc.

0.2474
+0.01004.21%
Post-market: 0.2465-0.0009-0.36%17:28 EST
Volume:3.08M
Turnover:768.25K
Market Cap:18.37M
PE:-0.22
High:0.2650
Open:0.2502
Low:0.2249
Close:0.2374
52wk High:1.43
52wk Low:0.1300
Shares:74.26M
Float Shares:50.38M
Volume Ratio:2.32
T/O Rate:6.11%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.1495
EPS(LYR):-1.4365
ROE:-813.88%
ROA:-105.08%
PB:-0.59
PE(LYR):-0.17

Loading ...

Bioatla Enters Into Agreements for up to $22.5 Million Flexible Financing

THOMSON REUTERS
·
Nov 21, 2025

Press Release: BioAtla Enters into Agreements for up to $22.5 Million Flexible Financing

Dow Jones
·
Nov 21, 2025

BioAtla Q3 Net Income USD -15.778 Million

Reuters
·
Nov 20, 2025

BioAtla’s Strategic Advancements and Promising Clinical Data Drive Buy Rating

TIPRANKS
·
Nov 16, 2025

BioAtla Q3 net loss widens to $15.8 mln

Reuters
·
Nov 14, 2025

BioAtla Q3 EPS $(0.27) Beats $(0.30) Estimate

Benzinga
·
Nov 14, 2025

BRIEF-BioAtla Q3 Net Income USD -15.778 Million

Reuters
·
Nov 14, 2025

BioAtla announces data on Mecbotamab Vedotin

TIPRANKS
·
Nov 07, 2025

BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, Demonstrates a Median Overall Survival (OS) of 21.5 months in Subtypes of Refractory Soft Tissue Sarcomas

GlobeNewswire
·
Nov 07, 2025

BioAtla to Announce Third Quarter 2025 Financial Results and Provide Business Highlights on November 13, 2025

GlobeNewswire
·
Nov 05, 2025

Bioatla Inc expected to post a loss of 30 cents a share - Earnings Preview

Reuters
·
Nov 04, 2025

BioAtla announces presentation of poster on Oz-V in OPSCC

TIPRANKS
·
Oct 23, 2025

BioAtla Presents Compelling Mechanistic Rationale for Targeting ROR2 with Ozuriftamab Vedotin (Oz-V) in Oropharyngeal Squamous Cell Carcinoma (OPSCC) at the Annual Conference of the International Papillomavirus Society

GlobeNewswire
·
Oct 23, 2025

BioAtla Says Cancer Therapy Showed 'Preliminary Prolonged Tumor Control' in Phase 1 Study

MT Newswires Live
·
Oct 20, 2025

BRIEF-BioAtla Presents Promising Interim Data from its Phase 1 Trial with BA3182 in Patients with Treatment Refractory Metastatic Adenocarcinoma at ESMO 2025

Reuters
·
Oct 20, 2025

BioAtla announces preliminary data from Phase 1 study of BA3182

TIPRANKS
·
Oct 20, 2025

Bioatla Presents Promising Interim Data From Its Phase 1 Trial With Ba3182 in Patients With Treatment Refractory Metastatic Adenocarcinoma at Esmo 2025

THOMSON REUTERS
·
Oct 20, 2025

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at SITC 2025

GlobeNewswire
·
Oct 03, 2025

BioAtla Inc. Granted Continued Nasdaq Listing with Conditions; Must Meet Equity and Bid Price Requirements by Early 2026

Reuters
·
Sep 23, 2025

BRIEF-BioAtla Updates FDA on Ozuriftamab Vedotin Plan for OPSCC After Positive Phase 2 Results

Reuters
·
Sep 08, 2025